Recent research have centered on the intersection of GLP-1|GIP|glucagon receptor activator therapies and dopamine signaling. While GLP activators are widely employed for addressing type 2 diabetes mellitus, their unexpected effects on reward circuits, specifically influenced by dopaminergic systems, are gaining substantial attention. This report… Read More